Drug information of Mibefradil

Mibefradil

Drug group:

Mibefradil belongs to a group of medicines called calcium channel blocking agents, or, more commonly, calcium channel blockers. Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

Mechanism of effect

Mibefradil is a tetralol calcium channel blocking agent that inhibits the influx of calcium ions across both the T (low-voltage) and L (high-voltage) calcium channels of cardiac and vascular smooth muscle, with a greater selectivity for T channels. Vasodilation occurs in vascular smooth muscle, causing a decrease in peripheral vascular resistance and a resulting decrease in blood pressure. Mibefradil causes a slight increase in cardiac output during chronic dosing. Mibefradil slows sinus and atrioventricular (AV) node conduction, producing a slight reduction in heart rate and a slight increase in the PR interval. It has also been shown to slightly lengthen the corrected sinus node recovery time and AH interval and to raise the Wenckebach point. The mechanism by which mibefradil reduces angina is not known, but is thought to be attributed to a reduction in heart rate, total peripheral resistance (afterload), and the heart rate–systolic blood pressure product at any given level of exercise. The result of these effects is a decrease in cardiac workload and myocardial oxygen demand.

Pharmacodynamic

Calcium channel blocking agents affect the movement of calcium into the cells of the heart and blood vessels. As a result, they relax blood vessels and increase the supply of blood and oxygen to the heart while reducing its workload.

Pharmacokinetics

Absorption: Bioavailability after a single dose is 70%. After multiple dosing, the proportion of mibefradil undergoing first-pass metabolism is reduced, resulting in a steady state bioavailability of approximately 90%. Food does not affect the rate or extent of absorption of mibefradil.

 

Protein binding: ≥ 99%, primarily to alpha 1-acid glycoprotein.

 

Metabolism: The two metabolic pathways that mibefradil undergoes are esterase-catalyzed hydrolysis of the ester side chain (producing an alcohol metabolite) and cytochrome P450 3A4-catalyzed oxidation (that becomes less important during chronic dosing). The pharmacologic effect of the metabolite is approximately 10% of that of the parent mibefradil.

 

Half life: 17 to 25 hours at steady state.

Drug indications

High Blood Pressure

Dosage

Usual Adult Dose for Hypertension and Angina Pectoris

Initial dose: 50 mg orally once a day with or without food.
Maintenance dose: The initial dose may be titrated upward to 100 mg orally once a day as needed and tolerated.

Interactions

Pirfenidone , nasal Mometasone , Maraviroc , Halofantrine , Erythromycin , Everolimus , Itraconazole , Irinotecan , Budesonide , Pimozide , lurasidone , Venetoclax , conivaptan , bosutinib , tolvaptan , levomethadyl acetate , neratinib , eszopiclone , Larotrectinib , gilteritinib , glasdegib , Ceritinib , Eliglustat , Ruxolitinib , Cariprazine , Cobimetinib , Temsirolimus , Naloxegol , ELBASVIR/GRAZOPREVIR , Cerivastatin , elagolix , ivosidenib , Sonidegib , Flibanserin , Edoxaban , Cabozantinib , Pimavanserin , Betrixaban , trabectedine , Duvelisib , encorafenib , midostaurin , Alfuzosin , Palbociclib , Butorphanol , olaparib , Ibrutinib , Isavuconazonium , Acalabrutinib , Darifenacin , red yeast rice , Fostamatinib , Terfenadine , Fesoterodine , Guanfacine , Hydrocodone , Ivacaftor , brigatinib , Copanlisib , Simeprevir , Dolasetron , Alfentanil , Osimertinib , Panobinostat , Ribociclib , Ticagrelor , Lomitapide , rasagiline , Axitinib , eletriptan , valbenazine , Ivabradine , Ranolazine , astemizole , Quetiapine , pravastatin , fluvastatin , Oxycodone , Azelastine , Daclatasvir , eplerenone , ergotamine , fentanyl , ergonovine , Lovastatin , Methylergonovin , Nilotinib , Nimodipine , Colchicine , Solifenacin , Disopyramide , Sirolimus , Cisapride , Cilostazol , Simvastatin , Fluticasone , Tamsulosin , Tizanidine , Thioridazine , Deflazacort , Docetaxel , Dihydroergotamine , Avanafil , Levomilnacipran , Brexpiprazole , Gefitinib , Dasatinib , ambrisentan , Vernakalant , voxelotor , Remoxipride , Fidaxomicin , Capmatinib

Alerts

Not available

Points of recommendation

Not available

Pregnancy level

Group c - Not adequate studies in pregnant women


Ask a Pharmacist


User's questions
    No comments yet.